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Modern pacemakers and implantable cardioverterdefibrillators (ICDs) can continuously monitor atrial rhythm. In patients with a pacemaker but without evidence for AF, device-detected atrial high-rate arrhythmias are common. 2, 3 These episodes, referred to as subclinical AF, are typically asymptomatic, of short duration (minutes to hours), and infrequent. 4 Thus, subclinical AF differs from permanent, persistent, and paroxysmal AF diagnosed by various forms of surface electrocardiogram (ECG) monitoring. However, although subclinical AF is associated with stroke, the increase in risk appears to be lower than that with clinical AF. 3, 5 Subclinical AF and stroke risk Several studies have shown an association between the presence of subclinical AF and the risk of stroke. The summarized results of the trials that have investigated the risk of stroke associated with subclinical AF have recently been published. 4 In the Mode Selection Trial in Sinus Node Dysfunction study, patients with sinus node dysfunction were randomized to dual-chamber rate-modulated or single-chamber ventricular pacing. In a subgroup analysis of this study, the presence of subclinical AF, defined as an atrial rate N220 beats/min and lasting ≥5 minutes, was independently associated with death or nonfatal stroke. 5 In the Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics (TRENDS) trial, patients with an indication for a pacemaker or an ICD and an additional risk factor for stroke were included.
2 Subclinical AF was defined as an episode of a rapid atrial rate N170 beats/min, lasting ≥20 seconds. At the end of a mean follow-up of 1.4 years, at least one episode of subclinical AF was observed in 47% of patients. In this study, the presence of subclinical AF was associated with thromboembolic risk, and this risk was related to the burden of subclinical AF. Subclinical AF duration of N5.5 h/d (the median value in the study) doubled the risk for thromboembolic events to 2.4%/y, whereas no increase in stroke risk was observed in patients with a lower burden of subclinical AF. 2 The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing (ASSERT) study included patients 65 years and older with a history of hypertension, a recent pacemaker or ICD implant, and no history of AF. Subclinical AF was defined as an episode of a rapid atrial rate N190 beats/min, lasting N6 minutes. Within 3 months after implantation, subclinical AF was detected in 10% of the patients. During a mean follow-up of 2.5 years, subclinical AF was detected in 35% of the patients. The presence of subclinical AF during the first 3 months after pacemaker implantation was associated with a 5-fold increase in the risk of developing clinical AF, and a 2.5-fold increase in the risk for ischemic stroke or systemic embolism. 3 Although subclinical AF is associated with stroke, this risk appears to be low compared with the stroke risk in patients with similar risk profiles and clinical AF. In TRENDS, the mean CHADS 2 score was 2.2, and the stroke rate in patients with episodes of subclinical AF was 2.4%/y. 2 In ASSERT, the mean CHADS 2 score was 2.2 and 2.3 in patients with and without subclinical AF, respectively. In patients with a baseline CHADS 2 score N2 and subclinical AF detected between enrollment and 3 months, the annual stroke rate was 3.78%. 3 Although this represents an almost 4-fold increase compared with the annual stroke risk of patients without subclinical AF during the first 3 months after pacemaker implantation, this is substantially lower than the N5.9% annual stroke risk of patients with clinical AF and a CHADS 2 score N2. Thus, after adjustment for risk factors for stroke, subclinical AF may be associated with a lower absolute stroke risk compared with clinical AF.
Anticoagulation therapy for stroke prevention in AF and subclinical AF The overall efficacy of anticoagulation therapy for stroke prevention in AF has been well established. 7 More recently, the efficacy and safety of non-vitamin K antagonist oral anticoagulants for stroke prevention have been established in pivotal phase 3 trials with thousands of patients. [8] [9] [10] [11] Overall, when compared with warfarin, non-vitamin K antagonist oral anticoagulants significantly reduced the risk of stroke, intracranial hemorrhage, and mortality, with similar risk for major bleeding but increased risk of gastrointestinal bleeding. 12 However, there were very few subclinical AF patients enrolled in any of these large trials. Patients with pacemakers especially tend to be extremely elderly and may have a high bleeding risk from anticoagulation. Thus, it is unknown whether there is a positive risk/benefit ratio for oral anticoagulation in patients with subclinical AF, and this question can only be conclusively answered by means of a randomized clinical trial. The rationale for such a trial is further supported by the observation that with prolonged monitoring via an implanted device, subclinical AF is frequently observed. For example, in ASSERT, the cumulative incidence of a subclinical AF episode of greater than 6 minutes by 3.5 years was almost 50%. Increasingly, physicians are using implanted devices such as the Medtronic Reveal recorder to detect arrhythmias in patients and even in those without symptoms. It is also likely that in the near future, detection of subclinical AF-like episodes will be possible by means of wearable devices such as smart watches. The increasingly common detection of subclinical AF and subclinical AF-like episodes will require better understanding of the role of anticoagulation in subclinical AF.
Given the uncertainty of the risk/benefit ratio of oral anticoagulation for stroke prevention in patients with device-detected subclinical AF, specific recommendations in most guidelines for AF management are scarce and rarely similar. The 2014 Canadian Cardiovascular Society Guidelines recommend oral anticoagulation therapy for patients with subclinical AF who are ≥65 years of age, with a CHADS 2 score ≥1 and episodes that last more than 24 hours, or for shorter episodes only if the patient is high risk, such as having a history of recent cryptogenic stroke. 13 The 2016 European Society of Cardiology guidelines, on the other hand, indicate that it is unclear whether subclinical AF implies the same therapeutic requirements as clinically overt AF, and recommend that patients with subclinical AF should undergo further ECG monitoring to document AF before initiating AF therapy.
14 Few patients with subclinical AF were enrolled in the trials that studied anticoagulation in patients with AF. Thus, the question of whether this therapeutic approach is beneficial for patients with subclinical AF remained to be investigated in a large randomized trial. A 4-country survey in Canada and Europe showed a heterogeneity in the opinions of cardiologists involved in the care of patients with pacemakers toward the role of anticoagulation therapy in patients with subclinical AF. 15 Importantly, most of them were willing to enroll patients in a randomized trial.
The ARTESiA trial was designed to determine whether treatment with apixaban compared with aspirin reduces the risk of stroke or systemic embolism in patients with subclinical AF and additional risk factors for stroke. The favorable risk/benefit ratio of apixaban shown in previous AF studies ( 8, 16 supports the hypothesis that prophylactic apixaban will have a net beneficial effect in patients with subclinical AF.
Methods

Study overview
ARTESiA (ClinicalTrials.govNo. NCT01938248) is a prospective, multicenter, double-blind, randomized controlled trial that will recruit patients with subclinical AF detected by either a pacemaker, ICD, or insertable cardiac monitor, and who also have other risk factors for stroke and no requirement for anticoagulation therapy. Eligible, consenting patients will be enrolled and randomized to receive aspirin or apixaban. The study will be conducted at approximately 230 sites in the United States, Canada, and Europe. This trial will be conducted in compliance with the study protocol, principles laid down in the Declaration of Helsinki, and Good Clinical Practice guidelines as defined by the International Conference on Harmonization where applicable. Before patient participation, written informed consent will be obtained from each patient or the patient's legally accepted representative, and will comply with the Declaration of Helsinki and applicable local regulations.
Study population
The ARTESiA trial will include approximately 4,000 participants. Key inclusion and exclusion criteria are shown in Table I . Device interrogation output (ie, an episode log) documenting at least one episode of subclinical AF ≥ 6 minutes in duration will be required as evidence of eligibility. The subclinical AF episode may have occurred at any time in the past. If the episode lasted b6 hours, electrogram documentation will also be collected for central verification. Episodes of subclinical AF ≥ 6 hours will not require electrogram documentation because previous studies have shown that there is a very high correlation between such reports and true subclinical AF. 17 For these longer episodes, device logs will be considered sufficient documentation to confirm eligibility. Patients with any single episode of subclinical AF N 24 hours in duration at any time before enrollment will not be included.
In addition to having subclinical AF, eligible patients must satisfy the following study criteria for stroke risk: (a) previous stroke, or transient ischemic attack, or systemic embolism, or age 75 years or greater; (b) age 65-74 years and 2 additional risk factors; or (c) age 55-64 years and 3 additional risk factors (Figure 1 ). The risk factors for stroke are female sex, hypertension, heart failure, diabetes, and vascular disease (coronary artery disease, peripheral artery disease, or aortic plaque) (Table II) .
Randomization, treatment, and follow-up
Enrolled patients will be randomized (interactive Web-based) in a 1:1 ratio between aspirin and apixaban ( Figure 2 ). Double-blind treatment will be achieved using a double-dummy technique. Each patient will take 3 study pills per day: a single aspirin or placebo aspirin and 2 doses of apixaban or placebo apixaban. Apixaban dosage will be 5 mg twice daily (or 2.5 mg twice daily for patients having ≥2 of the following characteristics: age ≥ 80 years, weight ≤ 60 kg, or serum creatinine ≥1.5 mg/dL). During the course of the trial, apixaban dosage will be down-titrated if patients develop 2 or more of these dose reduction criteria. Those assigned to aspirin will receive a dose of 81 mg once daily.
Follow-up will occur at 30 days after enrollment, at 6 months after enrollment, and every 6 months thereafter until the end of the study, with an anticipated mean follow-up of approximately 36 months. Because this is an event-driven study, the precise termination of follow-up will occur once 248 adjudicated primary efficacy outcome events have occurred.
Study outcomes
The primary efficacy outcome is a composite of stroke and systemic embolism. Stroke will be defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent nonvascular cause (eg, trauma, tumor, or infection). Signs or symptoms must last at least 24 hours, unless supported by clear evidence of cerebral infarction on diffusion-weighted magnetic resonance imaging. Available neuroimaging studies will be considered to support the clinical impression and to determine whether there is a demonstrable lesion compatible with an acute stroke. Strokes will be classified as ischemic, hemorrhagic, or unknown. Stroke includes transient ischemic attack with corresponding evidence of cerebral infarction on diffusion-weighted magnetic resonance imaging. 18 Stroke disability will be classified using the modified Rankin scale at day 7 or at hospital discharge (whichever comes first), and again at the next scheduled follow-up visit after the event.
A systemic arterial embolism will be considered to have occurred where there is clear evidence of abrupt occlusion of a systemic artery consistent with an embolic event. It will not include arterial occlusions that are not embolic, nor will it include pulmonary embolism. In addition to clinical signs and symptoms consistent with embolic arterial occlusion, there should be at least one of the following objective findings of arterial embolism: surgical report indicating evidence of arterial embolism, pathological specimens related to embolism removal, imaging evidence consistent with arterial embolism, or autopsy reports.
The main safety outcome will be the occurrence of clinically overt major bleeding as defined by the International Society of Thrombosis and Haemostasis criteria: fatal bleeding; symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; or bleeding causing an acute fall in hemoglobin level of ≥2 g/dL or leading to transfusion of 2 or more units of whole blood or red cells. 19 Secondary outcomes will include ischemic stroke, myocardial infarction, vascular death, total death (vascular and nonvascular), the composite of stroke, myocardial infarction, systemic embolism and total death, and the composite of stroke, myocardial infarction, systemic embolism, total death, and major bleeding. All primary events and major bleeding will be adjudicated.
Device interrogation data will be collected throughout study follow-up to allow for a better understanding of AF burden and subclinical AF frequency and duration in this population. In addition, the following cardiovascular outcomes that are common in this patient population will be assessed: clinical AF (detected by surface ECG), hospitalization for heart failure, cardioversion, and ablation for AF.
Sample size calculation and statistical analysis
Among ASSERT patients with risk factors similar to patients who will be enrolled in ARTESiA, the annual rate of stroke and systemic embolism was 2.75%. Assuming an event rate of 2.75% per year in the proposed population with an anticipated mean follow-up period of 3 years and using a 2-sided significance level of .05, a sample size of 3,719 is required to provide 80% power to detect a 35% 8. Meets criteria for requiring lower dose of apixaban AND has ongoing need for strong inhibitors of both CYP3A4 and P-glycoprotein (eg, ketoconazole, itraconazole, ritonavir, or clarithromycin)
9. Ongoing need for strong dual inducers of both CYP3A4 and P-glycoprotein (eg, rifampin, carbamazepine, phenytoin, St John's wort) 10 . Received an investigational drug in the past 30 d 11. Participants considered by the investigator to be unsuitable for the study for any of the following reasons:
• Not agreeable for treatment with either aspirin or apixaban or anticipated to have poor compliance on study drug treatment
• Unwilling to attend study follow-up visits
• Life expectancy b2 y due to concomitant disease 12. Women who are pregnant, breast-feeding, or of child-bearing potential without an acceptable form of contraception in place (sterilization, abstinence or other method with b1% failure rate)
Abbreviations: SCAF, subclinical AF; TIA, transient ischemic attack; SE, systemic embolism. ⁎ Risk factors: female gender, hypertension, heart failure, diabetes, vascular disease (coronary artery disease, peripheral artery disease, or aortic plaque).
relative risk reduction, allowing for a combined dropout and crossover rate of 8.5% over the course of the study. The study will enroll approximately 4,000 participants. A total of 248 primary outcome events will be required. The analysis of the main trial results will be performed following the intention-to-treat principle (ie, all patients randomized in the study will be included in the analysis). Patients will be included in their assigned treatment groups regardless of the actual treatment they received. An on-treatment analysis will include all treated patients (randomized patients who received at least one dose of the assigned study drug). In this analysis, patients will be categorized to the treatment group to which they were assigned unless they received the incorrect treatment.
Patients who received the incorrect treatment will be excluded from this analysis population. Follow-up will be censored at 6 days after discontinuation of study medication.
The rates of the primary efficacy outcome (stroke or systemic embolism) and primary safety outcome (major bleeding) will be presented for the 2 treatment groups using the Kaplan-Meier method, and comparisons between the groups will be performed using a log-rank test. Adjusted and unadjusted treatment effects as measured by the hazard ratio with 2-sided 95% CI will be derived by the Cox proportional hazards model. Six subgroup analyses of the main trial study outcome are prespecified to compare (1) patients whose longest baseline episode of subclinical AF is longer vs shorter than the median value for the study population, (2) patients with different CHA 2 DS 2 -VASc scores, (3) patients b75 and ≥75 years of age, (4) patients with and without history of stroke or transient ischemic attack, (5) patients with a chronic pacemaker/ICD/cardiac resynchronization therapy (≥2 years) vs newly implanted pacemaker/ICD/cardiac resynchronization therapy (b2 years) vs insertable cardiac monitor, and (6) patients with ICD vs pacemaker vs insertable cardiac monitor. Homogeneity of treatment effect in subgroups, both in magnitude and in direction, will be assessed by adding a covariate for the subgroup variable and the corresponding treatment-subgroup interaction to the respective nonstratified Cox proportional hazards model used in the main analysis. Significant interactions in the analysis of the primary outcome will be interpreted as "flags" to prompt further investigation. After the test of interaction, treatment effect will be estimated separately within each level of a subgroup variable using a stratified Cox proportional hazards model.
Steering and Data Monitoring Committees
The ARTESiA Steering Committee comprises the national leads from each participating country and oversees the design, execution, analysis, and reporting of the study, and Figure 1 Eligibility criteria for the ARTESiA trial. CAD, coronary artery disease; DM, diabetes; HF, heart failure; HTN, hypertension; PAD, peripheral artery disease; SE, systemic embolism; TIA, transient ischemic attack. will assign appropriate responsibilities to the other committees. The Steering Committee holds the primary responsibility for publication of the study results. This committee will convene regularly by teleconference for meetings to address policy issues and monitor study progress, execution, and management. An independent Data Monitoring Committee, composed of 1 neurologist, 2 cardiologists, 1 thrombosis expert, and 1 statistician, will review serious adverse events, adverse drug effects, and primary outcome data on a 6-month basis and reports to the Steering Committee. Two formal interim analyses will be done after 82 and 164 primary outcome events have occurred.
The Data Monitoring Committee may in exceptional circumstances recommend termination of the study for a safety concern that is assessed to outweigh potential benefits. No formal boundaries will be used for terminating the study for safety reasons, but clear and consistent evidence of net harm that overrides any benefit should be apparent. In the case that risk outweighs benefit in these 2 important outcomes, the committee may recommend that the study be stopped early for "harm."
The modified Haybittle-Peto rule will be used to guide the decision regarding early stopping: a reduction of 4 SDs (α = .00006) in the analysis of the primary outcome at the first interim analysis or 3 SDs (α = .0027) at the second interim analysis. If the monitoring boundary is crossed at either of the 2 interim analyses, a second look will be conducted after at least 3 to 6 months to confirm the boundary remains crossed and that the trend in treatment effect is not temporary. The αlevel for the final analysis will remain the conventional .05 given the paucity of interim analyses, their extremely low αlevels, and the requirement for confirmation with subsequent analyses.
Support
ARTESiA is an investigator-initiated study, supported by grants from the Canadian Institutes for Health Research, Canadian Stroke Prevention Intervention Network, the Bristol-Myers Squibb and Pfizer Alliance, Hamilton Health Sciences Foundation, and Medtronic, Inc. The authors are solely responsible for the design and conduct of this study, all study analyses, and the drafting and editing of the manuscript and its final contents.
Discussion
Subclinical AF is characterized by relatively short episodes of atrial high-rate arrhythmias that are detected only with continuous monitoring and are mostly asymptomatic. Subclinical AF differs from clinically overt AF, which occurs more often, with symptoms, and is documented on ECG. Several studies have shown an association between the presence of subclinical AF and the risk of stroke. [2] [3] [4] [5] However, there is debate on the minimum duration of subclinical AF that is required to confer this stroke risk. For eligibility in the ARTESiA trial, subclinical AF episode duration between 6 minutes and 24 hours was chosen based primarily on the ASSERT study, because it was observed that episodes of subclinical AF lasting at least 6 minutes were associated with an increased risk of stroke, and when episodes of subclinical AF were longer than 24 hours, this risk was much higher. A recent publication of the Canadian Cardiovascular Society recommended oral anticoagulation therapy for patients with subclinical AF lasting N24 hours when the patient is aged ≥65 years or with CHADS 2 score ≥ 1, or for shorter episodes if the patient is considered to be at high risk. 13 The 2016 European Society of Cardiology guidelines limit the consideration of oral anticoagulants in patients with subclinical AF, except for special circumstances. 14 A recent review on stroke prevention in patients with subclinical AF suggests anticoagulating patients with subclinical AF if a history of ischemic stroke is present. 20 Observations from the ASSERT II trial, however, may challenge the importance of history of ischemic stroke in this setting. Using an implantable loop recorder, the ASSERT II trial studied the prevalence of subclinical AF among older individuals without pacemakers. With an annual incidence of 34.4%, subclinical AF episodes ≥5 minutes were common in asymptomatic elderly patients. Patients with Figure 2 ARTESiA trial design. bid, twice daily; ISTH, International Society of Thrombosis and Haemostasis; OAC, oral anticoagulant; OD, once daily; TIA, transient ischemic attack. *A 2.5-mg dose of apixaban will be given twice daily for patients who have 2 or more of the following characteristics: age ≥ 80 years, weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL. prior stroke were not more likely to have subclinical AF than patients without prior stroke. 21 The current need for scientific evidence investigating stroke prevention in device-detected subclinical AF has been highlighted. 22 Whether subclinical AF is the same direct risk factor for stroke as clinical AF or is only a risk marker with a different mechanism is unclear. Therefore, patients with subclinical AF may respond differently to anticoagulants than patients with clinical AF. Results from TRENDS, the Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk (IMPACT) study, and a time-dependent analysis for ASSERT all indicate that there is no clear temporal association between episodes of subclinical AF and stroke. 2, 23, 24 The absence of a temporal relationship between subclinical AF and the occurrence of stroke challenges the conventional understanding of a mechanistic relationship between atrial stasis, clot formation, and embolism. Stroke in patients with subclinical AF may be delayed or may be caused by a different factor. IMPACT was the first trial of anticoagulation in device-detected subclinical AF but used a complex treatment strategy, stopping treatment if no further subclinical AF episodes were seen in a period of time. 24 Early initiation of anticoagulation based on device-detected subclinical AF did not improve outcomes, in part because of temporal dissociation between AF and stroke, and possibly because of stroke mechanisms independent of subclinical AF. 25 In this trial, a possible explanation for the lack of observed benefit of the monitoring strategy is that the idea that stroke risk increases for a defined period after subclinical AF may be incorrect. Previous data have suggested that in most cases of subclinical AF-associated stroke, no AF occurred within 1 to 3 months of the stroke. Another important issue was the use of a composite primary outcome including stroke and major bleeding. The components of this composite outcome may have offset each other, which could have contributed to a neutral result. 25 In clinical practice, the relationship between subclinical AF and stroke is likely complex, and different for different patients: in some, a temporally linked, causal relationship, whereas in others, simply a marker of stroke risk. Therefore, the results of the IMPACT trial do not support urgent initiation or any later withdrawal of anticoagulation in response to incident subclinical AF or its termination, and argue instead for anticoagulation based on more comprehensive, individualized assessment of risk and benefit. Additional studies like ARTESiA will help elucidate stroke mechanisms in patients with advanced heart disease to inform anticoagulation decision making for AF detected by implanted cardiac rhythm management devices.
Apixaban is a factor Xa inhibitor that has been shown to be effective in a variety of conditions where oral anticoagulation can be used, including the reduction of venous thromboembolism and stroke. In the AVERROES and ARISTOTLE trials, apixaban was effective and safe for patients with nonvalvular AF compared with aspirin or dose-adjusted warfarin. 8, 16 The Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment (AMPLIFY-EXT) study showed that extended use of apixaban was safe, with similar rates of major bleeds when compared with placebo. 26 Thus, the consistently favorable risk/benefit ratio of apixaban led to the selection of apixaban in the design of ARTESiA.
Aspirin was chosen as the control for the ARTESiA study because it is a common medication for secondary prevention in this population of patients with multiple risk factors, and modestly reduces the risk of ischemic stroke. Instead of combining the use of apixaban and aspirin, which would likely increase the risk of bleeding events in these patients, we have chosen to compare apixaban with aspirin. Our study, however, will allow the use of open-label aspirin up to 100 mg/d in addition to study medication in situations where the treating physician considers aspirin to be appropriate.
Finally, patients who develop symptomatic clinical AF documented by surface ECG during the study period should be taken off the study drug and switched to non-study anticoagulant therapy as recommended by current guidelines. If a clinical indication for anticoagulation or dual antiplatelet therapy arises, the study drug will be discontinued or interrupted. If patients develop subclinical AF with episode duration N24 hours, the decision to discontinue blinded study drug and start non-study anticoagulant therapy will be left to the discretion of the investigator. Participants will continue with follow-up and may restart study medications if and when the clinical indication for these other therapies resolves. Unblinding of study medication will be avoided unless knowledge of the treatment allocation is required to make an urgent treatment decision.
Conclusions
The ARTESiA trial will compare apixaban with aspirin to reduce the risk of stroke in patients with subclinical AF and additional risk factors for stroke. The study findings will generate evidence to address this gap in scientific knowledge and will help inform antithrombotic strategies for these patients.
Disclosures
Dr Lopes's disclosures are available at https://dcri.org/ about-us/conflict-of-interest. Dr Alings has served on advisory boards/speaker bureau for Bayer, Bristol-Myers Squib, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer. Dr Connolly has received consulting fees and research support from Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Bayer, Portola, Medtronic, St Jude Medical, and Daiichi Sankyo. Dr Granger has received consulting and research funding from Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Bayer/Janssen, and Daiichi Sankyo. Dr Mazuecos has received speaking and consulting fees from St Jude Medical.
